Core Insights - Pfizer's Chief Corporate Affairs Officer, Sally Susman, will step down by the end of 2025, marking the end of her nearly 20-year tenure at the company, during which she navigated complex political and policy environments across five U.S. presidential terms [1][2] - Susman's departure is part of Pfizer's global restructuring plan, which aims to cut over $7 billion in expenses by 2027 due to declining demand for COVID-19 vaccines and treatments [2] Group 1 - Sally Susman has been a key figure at Pfizer, serving as a spokesperson, government relations bridge, and patient advocate during her nearly two-decade career [1] - Under her leadership, Pfizer effectively managed its public image and maintained public trust during significant challenges, including patent expirations and pricing controversies [1][2] - Susman's team played a crucial role during the COVID-19 pandemic, facilitating global communication for Pfizer's vaccine and treatment Paxlovid amid unprecedented public health pressures [2] Group 2 - The restructuring will involve the disbanding of Susman's core department, with responsibilities being redistributed among five executives, indicating the importance of her role and Pfizer's commitment to cost control [2] - The changes at Pfizer may set a precedent for the pharmaceutical industry, as the company is often viewed as a benchmark, highlighting the challenge of balancing cost reduction with innovation in drug development [2]